Key Takeaways for AstraZeneca Stock as of July 2026
- Adjusted EPS Beat: Adjusted EPS hit $2.63, topping the $2.47 estimate by 6.28% and rising 21.20% YoY.
- Guidance Held: Management reiterated its FY26 outlook for mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant exchange rates.
- Pipeline Whiplash: A failed CARDIO-TTRansform trial for Wainua cost AstraZeneca one bet, but positive Phase III wins for tozorakimab in COPD and sone-ve in gastric cancer pushed combined peak sales potential above $8 billion.
- CEO Rules Out M&A: CEO Pascal Soriot rejected the idea that AstraZeneca needs new business development, telling analysts on the call, “the answer is no, we don’t need more BD to deliver.”
AstraZeneca’s Q2 Earnings Show a Failed Heart Trial Offset by Two Pipeline Wins
AstraZeneca (AZN) stock is trading on a quarter where the headline numbers told only half the story. Total revenue for the period ended June 30, 2026 came in at $15,384 million, up 6.41% year over year, while adjusted earnings per share of $2.63 beat the Street’s $2.47 estimate by 6.28% and jumped 21.20% from a year ago. GAAP EPS told a rougher tale, falling to $1.61 against a $2.01 estimate, a 20.02% miss that also marked an 18.27% drop from the first quarter.
EBITDA compounded that divergence, printing $5,092 million against a $7,348 million estimate, a 30.71% shortfall that pulled margins down 1,457 basis points versus forecast to 33.10%. EBIT told a cleaner story. At $5,158 million, it edged the estimate by 1.13% and expanded margins 182 basis points year over year to 33.53%. Management pointed to seasonal gross margin patterns, expecting stable to slightly higher core gross margin for the full year even as second-half margins typically soften on lower-margin products like FluMist and Beyfortus.
Segment growth explains the gap between the headline 6% revenue increase and the underlying momentum in AstraZeneca stock. Oncology revenue grew 15% in the first half to $14.1 billion, while biopharmaceuticals revenue fell 5% to $11.2 billion as generic competition hit Farxiga, Brilinta and roxadustat. Strip out those two lapsing products and total revenue actually grew 11%, a gap management uses to argue the portfolio’s underlying strength outweighs the loss-of-exclusivity drag.
That framing collided with reality on Wainua. The Phase III CARDIO-TTRansform trial testing the gene silencer against transthyretin-mediated amyloid cardiomyopathy missed its primary composite endpoint of cardiovascular mortality and recurrent events, a setback CEO Pascal Soriot called disappointing for the team and the patients on the Q2 earnings call. But two other bets more than covered the loss. Tozorakimab hit its OBERON and TITANIA endpoints in COPD (chronic obstructive pulmonary disease), a drug AstraZeneca itself gave low odds of success, and management now pegs its peak sales above $5 billion. Sone-ve, AstraZeneca’s first wholly owned antibody-drug conjugate, posted a statistically significant overall survival benefit in gastric cancer, adding an estimated $3 billion to $5 billion in peak sales potential.
Management reiterated full-year guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth at constant currency, unchanged since the year began. Asked directly whether AstraZeneca stock needs a large acquisition to sustain growth past 2032, Soriot was unequivocal: “Well, I think on this one, I can be very clear. The answer is no, we don’t need more BD to deliver.” He pointed to an aggregate pipeline success rate near 60%, in line with industry norms, as the basis for that confidence, even with AstraZeneca’s own track record running above 75%.
TIKR Prices AstraZeneca Stock at $278, a 62% Return Through 2030
TIKR’s mid-case model values AstraZeneca stock at $278 by December 2030, implying 62% total return from the current price of $171, or 12% annualized over 4.4 years.
A 62% total return over 4.4 years works out to a low-double-digit annualized rate, the kind of compounding that positions AstraZeneca stock as a growth name carrying dividend-like ballast rather than a straight defensive pharmaceutical holding.
That target rests on the same pipeline math the quarter just demonstrated. Management’s aggregate probability-weighted framework absorbed the Wainua failure and still came out ahead on tozorakimab and sone-ve alone, and with low double-digit core EPS growth reiterated and the $80 billion 2030 revenue ambition intact, the model is pricing a business that keeps compounding even when individual bets miss.
Should You Invest in AstraZeneca?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AstraZeneca PLC stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AstraZeneca PLC alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze AZN stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
